The concept of applying SNP-based panels to assess disease risk is not novel, but we remain in the early stages of understanding how genomics plays a role in risk assessment and disease prognosis. A better understanding of both gene-gene interactions and how these interactions affect risk assessment for patients are paramount in moving such technology forward. Until then, it is premature to use these panels in the clinic.
Dr. Hulick is a medical geneticist at NorthShore University HealthSystem, Evanston, Ill., and a clinical assistant professor at the University of Chicago. He reported having no conflicts of interest.